Atherosclerotic Cardiovascular Disease Market is expected to reach US$195.8 billion in 2030 with a growth rate of 3.8%.

Atherosclerotic cardiovascular disease (ASCVD) refers to conditions caused by plaque buildup in the arteries leading to reduced blood flow. It includes coronary artery disease, carotid artery disease, peripheral arterial disease, and cerebrovascular disease. ASCVD is the leading cause of mortality worldwide.

The growth drivers for the ASCVD market include the rising prevalence of risk factors like obesity, hypertension, diabetes, and sedentary lifestyles. As per the CDC, over 130 million Americans are expected to have some form of CVD by 2035 due to the high rates of these risk factors. Advancements in treatment approaches like PCSK9 inhibitor drugs, minimally invasive surgeries, and digital health monitoring solutions are also boosting market growth. For instance, the FDA recently approved inclisiran, a PCSK9 inhibitor by Novartis, to treat primary hyperlipidemia.

The Atherosclerotic Cardiovascular Disease Market is undergoing a shift towards early diagnosis and prevention. Companies are focused on developing novel biomarkers and point-of-care diagnostic tests for the timely detection of atherosclerosis progression before complications arise. The integration of digital health solutions like wearables and mobile apps with ASCVD treatment enables remote monitoring and improves patient engagement. Further, healthcare systems are moving from volume to value-based care, with an emphasis on patient outcomes rather than services provided. These trends are revolutionizing ASCVD patient management.

Drivers:

• Rising prevalence of risk factors like obesity, hypertension, diabetes, and sedentary lifestyles is increasing the patient pool needing treatment and management. As per CDC estimates, 45% of American adults suffer from hypertension.
• Advancements in treatment approaches like PCSK9 inhibitors, minimally invasive surgeries, and digital health monitoring are boosting diagnosis, management, and outcomes.

Trends:

• Increasing focus on early diagnosis and prevention before onset of complications.
• Shift towards value-based care and patient-centric treatment pathways.

Opportunity:

• Huge scope exists for development of therapies that can reverse atherosclerosis by targeting root pathology rather than just managing risk factors.

Key Report Insights:

• North America accounted for over 40% of the Atherosclerotic Cardiovascular Disease Market share in 2022. Prominent companies with strong regional presence include Amgen, Johnson & Johnson, Abbott, Medtronic, Boston Scientific. High obesity and diabetes rates are key drivers in the region.
• Europe held the second largest share of over 30% in 2022. Key players in the region include AstraZeneca, Bayer, Sanofi, Siemens Healthineers. The rising geriatric population and changing treatment patterns boost regional growth.
• Leading companies operating in the global ASCVD market include Amgen, Regeneron, Sanofi, Novartis, Pfizer, Merck, AstraZeneca, Johnson & Johnson, Abbott Laboratories, Teva Pharmaceuticals.

Atherosclerotic Cardiovascular Disease Market Segmentation:

By Therapeutics

• Anti-platelet Agents
• Beta-blockers
• ACE Inhibitors
• ARBs
• Statins
• Calcium Channel Blockers
• Others

By Disease Type

• Coronary Artery Disease
• Carotid Artery Disease
• Peripheral Arterial Disease
• Cerebrovascular Disease
• Renal Artery Stenosis
• Aortic Aneurysm
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • Israel
  • South Africa
  • North Africa
  • Central Africa
  • Rest of the Middle East

Definition:

“The Atherosclerotic Cardiovascular Disease (ASCVD) Market encompasses therapies, diagnostics, and devices used for treating conditions caused due to plaque accumulation in the artery walls, which restricts blood flow. It includes coronary artery disease, cerebrovascular disease, peripheral arterial disease, among others. ASCVD is responsible for over 75% of all cardiovascular disease cases and represents the leading cause of mortality globally. The market comprises pharmaceutical drugs, surgical interventions, and medical devices focused on lowering lipid levels, blood pressure control, revascularization procedures, and Imaging techniques for early detection and diagnosis.”